value & access

Views & Analysis

Ana Céspedes, senior vice president of global marketing and strategy at EMD Serono, on the evolution of the Value & Access function.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

value &amp; access